Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PDL restructuring

PDLI said it plans to sell its commercial operations and shift its focus to discovering and developing antibodies for cancer and immunological diseases. The company also said it terminated its

Read the full 305 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE